A couple months may not seem like a long time, but when you're diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference.
Keep Reading →
September 13 - Dividend Stocks, News
As the CEO of ConocoPhillips (NYSE:COP), the largest independent oil company in the nation, Ryan Lance was happy to address the pros and cons of hydraulic fracturing - or "fracking...
Keep Reading →
September 12 - Dividend Stocks, News
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Keep Reading →
September 6 - News
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Keep Reading →
September 5 - News
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Keep Reading →
September 5 - News
Peregrine Pharmaceuticals (NASDAQ:PPHM) will release its latest quarterly report on Monday, and investors are under no illusions that the company will avoid losing money again...
Keep Reading →
September 5 - News
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
Keep Reading →
September 4 - News
In the financial world, there are many methods market participants can use to track the equity markets.
Keep Reading →
September 3 - News
Now, according to many investors, hedge funds are seen as overrated, outdated investment tools of a period lost to current times.
Keep Reading →
August 30 - News
The phrase "PDUFA date" is thrown around frequently when discussing biotech and pharma companies.
Keep Reading →
August 27 - News
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments.
Keep Reading →
August 26 - News
Curis, Inc. (NASDAQ:CRIS) and Roche Holding Ltd.
Keep Reading →
August 26 - News
In the eyes of many of your peers, hedge funds are perceived as useless, outdated financial tools of a forgotten age.
Keep Reading →
August 22 - News
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
Keep Reading →
August 20 - News
The battle against cancer is both valiant and frustrating.
Keep Reading →
August 14 - News
Eli Lilly & Co. (NYSE:LLY) was in 35 hedge funds' portfolio at the end of March. LLY investors should be aware of a decrease in hedge fund interest recently.
Keep Reading →
August 13 - News
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News
Ariad Pharmaceuticals, Inc.
Keep Reading →
August 8 - News
A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018.
Keep Reading →
August 6 - News
The National Headache Foundation (yes, there is such an organization) says that around 30 million Americans suffer from migraines.
Keep Reading →
August 6 - News
In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies.
Keep Reading →
August 3 - News
Vical Incorporated (NASDAQ:VICL) announced its second-quarter results on Thursday.
Keep Reading →
August 2 - News
Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle...
Keep Reading →
August 1 - News
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
Keep Reading →
July 31 - News
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) announced last week that they are making another attempt at U.S.
Keep Reading →
July 30 - News
Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year.
Keep Reading →
July 28 - News
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Keep Reading →
July 22 - News
According to multiple reports , Harvard researchers Timothy Henrich and Daniel Kuritzkes have recently noted a surprising side-effect to cancer treatments performed on two separate...
Keep Reading →
July 22 - News
There's little denying that the technological, research, and medicinal aspects of patient care are improving at breakneck speed.
Keep Reading →
July 22 - News
The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals.
Keep Reading →
July 22 - News
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial...
Keep Reading →
July 18 - News
With all of the factors we have to worry about in our everyday lives, it is somewhat a wonder that we're not only able to survive, but thrive, as a society.
Keep Reading →
July 15 - News
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Keep Reading →
July 15 - News
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 12 - News
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)'s door frequently these days.
Keep Reading →
July 11 - News
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 10 - News
We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses.
Keep Reading →
July 8 - News
A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ:MDCO).
Keep Reading →
July 5 - News
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Keep Reading →
July 5 - News
When looking for the best dividend stocks, it's usually best to not chase the highest dividend.
Keep Reading →
July 2 - News
Over the last three decades I have seen my share of bull and bear markets.
Keep Reading →
July 1 - News
Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June.
Keep Reading →
July 1 - News
Companies know that to attract regular income-seeking investors, it helps to pay out high dividends.
Keep Reading →
July 1 - News
Merck & Co., Inc. (NYSE:MRK) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth.
Keep Reading →
July 1 - News
An entity with deep pockets is looking to buy boatloads of Pfizer Inc. (NYSE:PFE) stock. And we're talking yacht-sized boatloads -- not canoe-sized ones.
Keep Reading →
July 1 - News
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) just can't catch a break.
Keep Reading →
June 28 - News
After a series of failures, one is forced to wonder whether the medical fraternity, including the research and development wing of Eli Lilly & Co.
Keep Reading →
June 27 - News
After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some good news to report.
Keep Reading →
June 27 - News
